Enclomiphene vs Sermorelin
Well Studied vs Well Studied
monitor Mechanism-based · 47% Both Enclomiphene and Sermorelin act on estrogen receptors. Receptor competition may reduce effectiveness of one or both. Using multiple SERMs simultaneously is generally not recommended — choose one.
Molecular Data
Enclomiphene Sermorelin
Weight 405.96 Da 3,358 Da
Half-life ~10 hours 10-12 minutes
Chain — 29 amino acids
Type Trans-isomer of clomifene (selective estrogen receptor modulator) GHRH analog
Key Benefits
Enclomiphene
01 Raises endogenous testosterone by stimulating the HPTA axis
02 Preserves fertility and spermatogenesis (unlike exogenous testosterone)
03 No estrogenic agonist activity (unlike racemic clomifene/Clomid)
04 Oral dosing with no injections required
05 Does not suppress the HPTA or cause testicular atrophy
06 Effective for post-cycle therapy and secondary hypogonadism
07 Well-tolerated with a favorable side effect profile
Sermorelin
01 FDA-proven efficacy
02 Maintains natural GH pulsatile patterns
03 Preserves pituitary function
04 1.26kg lean mass increase documented in elderly
05 IGF-1 mediated anabolic effects
06 Allows natural feedback regulation
Dosing Protocols
Enclomiphene
12.5-25mg oral daily / Once daily (morning preferred)
Sermorelin
200-300mcg per dose (up to 500mcg for athletic performance) / Once daily at bedtime (aligns with natural GH pulse)
Anti-aging/Longevity 200-300mcg Once at bedtime
Athletic Performance 300-500mcg Once at bedtime
Body Composition 200mcg 5 days weekly
Combination Therapy 200mcg + GHRP Once daily
Side Effects
Enclomiphene
Headache
Nausea or mild gastrointestinal discomfort
Hot flashes or flushing
Mood changes (irritability or emotional sensitivity)
Fatigue during initial adjustment
Sermorelin
Injection site reactions (16.7% of patients - generally mild)
Nasal irritation (intranasal route)
Contraindications
Known hypersensitivity to clomifene or enclomiphene
Pre-existing liver disease or significantly elevated liver enzymes
Active or history of thromboembolic disorders
Pregnancy or women who may become pregnant (teratogenic risk)
Primary hypogonadism (testicular failure -- enclomiphene requires functional testes)
Pituitary tumors or undiagnosed pituitary pathology
Active malignancy
Pituitary tumors
Pregnancy
Research Evidence
Enclomiphene Sermorelin
Status Well Studied Well Studied
References 5 studies 5 studies
Latest — November 2024
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.